Phathom Pharmaceuticals, Inc.
PHAT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001783183
No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 30, 2026, 1:20 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $221.2M (126.3% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Reported | Jan 7, 2026 | Mar 6, 2025 | Mar 7, 2024 | Feb 28, 2023 | Mar 1, 2022 |
| Revenue | $175.1M | $55.3M | $682.0K | – | – |
| Cost of revenue | $22.6M | $7.97M | $167.0K | – | – |
| Gross profit | $152.5M | $47.3M | $515.0K | – | – |
| Operating expenses | $312.5M | $324.7M | $167.8M | $172.4M | $135.1M |
| Research and development | $32.8M | $34.1M | $49.9M | $71.4M | $72.3M |
| Selling, general and administrative | $279.7M | $290.7M | $117.9M | $101.0M | $62.7M |
| Operating income | -$160.0M | -$277.5M | -$167.3M | -$172.4M | -$135.1M |
| Interest expense | – | – | $42.0M | $27.3M | $6.79M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$221.2M | -$334.3M | -$201.6M | -$197.7M | -$143.9M |
| EPS, basic | $-3.03 | $-5.29 | $-3.93 | $-5.05 | – |
| EPS, diluted | $-3.03 | $-5.29 | $-3.93 | $-5.05 | – |
| Weighted shares, basic | 72.9M | 63.2M | 51.3M | 39.1M | – |
| Weighted shares, diluted | 72.9M | 63.2M | 51.3M | 39.1M | – |
| Margins and growth | |||||
| Gross margin | 87.1% | 85.6% | 75.5% | – | – |
| Operating margin | -91.4% | -502.2% | -24532.6% | – | – |
| Net margin | -126.3% | -605.1% | -29558.9% | – | – |
| Revenue growth, year over year | +216.9% | +8,001.5% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Reported | Jan 7, 2026 | Mar 6, 2025 | Mar 7, 2024 | Feb 28, 2023 | Mar 1, 2022 |
| Cash and equivalents | $130.0M | $297.3M | $381.4M | $155.4M | $183.3M |
| Accounts receivable | $78.1M | $38.8M | $1.64M | – | – |
| Inventory | $5.52M | $3.21M | $1.21M | – | – |
| Total current assets | $229.0M | $360.1M | $397.4M | $160.5M | $186.5M |
| Property, plant and equipment | $1.06M | $1.48M | $2.15M | $1.21M | $650.0K |
| Total assets | $259.1M | $378.3M | $413.8M | $164.8M | $189.4M |
| Accounts payable | $4.98M | $10.5M | $12.6M | $10.0M | $5.15M |
| Short-term debt | $0 | $0 | $0 | – | – |
| Total current liabilities | $132.0M | $85.7M | $38.8M | $26.2M | $18.9M |
| Long-term debt | $209.1M | $201.4M | $137.8M | $95.3M | $89.7M |
| Total liabilities | $697.3M | $631.9M | $486.6M | $239.6M | $117.3M |
| Shareholders' equity | -$438.2M | -$253.6M | -$72.8M | -$74.8M | $72.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Reported | Jan 7, 2026 | Mar 6, 2025 | Mar 7, 2024 | Feb 28, 2023 | Mar 1, 2022 |
| Operating cash flow | -$166.8M | -$266.8M | -$137.6M | -$146.5M | -$148.6M |
| Capital expenditures | $229.0K | $135.0K | $1.63M | $1.04M | $328.0K |
| Free cash flow | -$167.0M | -$266.9M | -$139.2M | -$147.6M | -$148.9M |
| Depreciation and amortization | $633.0K | $795.0K | $575.0K | $620.0K | $521.0K |
| Stock-based compensation | $28.7M | $24.0M | $45.0M | $24.1M | $16.8M |
| Investing cash flow | -$229.0K | -$135.0K | -$1.63M | -$1.04M | -$328.0K |
| Financing cash flow | -$288.0K | $182.8M | $367.6M | $120.0M | $44.7M |
| Net change in cash | -$167.3M | -$84.1M | $228.4M | -$27.5M | -$104.2M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 16.4% | 43.5% | 6601.9% | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 27, 2026 | 81.3M | +14.3% | SEC |
| Jul 27, 2026 | 80.9M | +14.0% | SEC |
| Apr 27, 2026 | 79.8M | +14.2% | SEC |
| Feb 23, 2026 | 78.8M | +13.2% | SEC |
| Oct 27, 2025 | 71.1M | +4.0% | SEC |
| Aug 4, 2025 | 70.9M | +19.0% | SEC |
| Apr 29, 2025 | 69.8M | +19.3% | SEC |
| Mar 3, 2025 | 69.6M | +19.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.